Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.76 USD | +2.51% | +19.38% | +31.97% |
May. 07 | Cogent Biosciences Q1 Loss Widens | MT |
May. 07 | Cogent Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Business Summary
Number of employees: 164
Managers
Managers | Title | Age | Since |
---|---|---|---|
Andrew Robbins
CEO | Chief Executive Officer | 48 | 20-10-22 |
John Green
DFI | Director of Finance/CFO | 43 | 18-05-31 |
Rachael Easton
CTO | Chief Tech/Sci/R&D Officer | - | 22-11-27 |
Brad Barnett
CTO | Chief Tech/Sci/R&D Officer | - | - |
Jessica Sachs
CTO | Chief Tech/Sci/R&D Officer | 49 | 17-03-31 |
John Robinson
CTO | Chief Tech/Sci/R&D Officer | 50 | 21-04-05 |
Christi Waarich
IRC | Investor Relations Contact | - | - |
Dana Martin
PRN | Corporate Officer/Principal | - | 21-10-31 |
Sara Saltzman
LAW | General Counsel | - | 18-12-31 |
Human Resources Officer | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Arlene Morris
BRD | Director/Board Member | 72 | 19-07-25 |
Matthew Ros
BRD | Director/Board Member | 57 | 19-07-25 |
Todd Shegog
BRD | Director/Board Member | 59 | 21-02-21 |
Karen Ferrante
BRD | Director/Board Member | 66 | 18-01-31 |
Andrew Robbins
CEO | Chief Executive Officer | 48 | 20-10-22 |
Peter Harwin
CHM | Chairman | 38 | 20-07-05 |
Chris Cain
BRD | Director/Board Member | 40 | 20-07-05 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 95,613,396 | 94,354,142 ( 98.68 %) | 0 | 98.68 % |
Stock B | 0 | 74,465 | 0 | 0 |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.97% | 724M | |
+10.44% | 106B | |
+0.82% | 104B | |
+6.72% | 23.25B | |
-13.89% | 22.5B | |
-6.64% | 18.7B | |
-37.26% | 17.95B | |
-10.98% | 16.99B | |
+8.67% | 14.26B | |
+41.08% | 12.76B |
- Stock Market
- Equities
- COGT Stock
- Company Cogent Biosciences, Inc.